Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays.

Wu X, Xu X, Gu R, Wang Z, Chen H, Xu K, Zhang M, Hutton J, Yang T.

Autoimmunity. 2012 Mar;45(2):176-85. doi: 10.3109/08916934.2011.622014. Epub 2012 Jan 20.

PMID:
22260783
2.

Pancreatic islet autoimmunity.

Boitard C.

Presse Med. 2012 Dec;41(12 P 2):e636-50. doi: 10.1016/j.lpm.2012.10.003. Epub 2012 Nov 22. Review.

PMID:
23182678
3.

Islet autoantigens: structure, function, localization, and regulation.

Arvan P, Pietropaolo M, Ostrov D, Rhodes CJ.

Cold Spring Harb Perspect Med. 2012 Aug 1;2(8). pii: a007658. doi: 10.1101/cshperspect.a007658. Review.

4.

Different role of zinc transporter 8 between type 1 diabetes mellitus and type 2 diabetes mellitus.

Yi B, Huang G, Zhou Z.

J Diabetes Investig. 2016 Jul;7(4):459-65. doi: 10.1111/jdi.12441. Epub 2016 Jan 9. Review.

5.

The beta cell immunopeptidome.

Dudek NL, Purcell AW.

Vitam Horm. 2014;95:115-44. doi: 10.1016/B978-0-12-800174-5.00005-3. Review.

PMID:
24559916
6.

Current and Future Clinical Applications of Zinc Transporter-8 in Type 1 Diabetes Mellitus.

Yi B, Huang G, Zhou ZG.

Chin Med J (Engl). 2015 Sep 5;128(17):2387-94. doi: 10.4103/0366-6999.163389. Review.

7.

ZnT8 and type 1 diabetes.

Kawasaki E.

Endocr J. 2012;59(7):531-7. Epub 2012 Mar 8. Review.

8.

Changing faces, unmasking the beta-cell: post-translational modification of antigens in type 1 diabetes.

van Lummel M, Zaldumbide A, Roep BO.

Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):299-306. doi: 10.1097/MED.0b013e3283631417. Review.

PMID:
23770733
9.

[Genetic and molecular background in autoimmune diabetes mellitus].

Kantárová D, Prídavková D, Ságová I, Vrlík M, Mikler J, Buc M.

Epidemiol Mikrobiol Imunol. 2015 Sep;64(3):121-9. Review. Czech.

PMID:
26448299
10.

Experiments by nature: lessons on type 1 diabetes.

Battaglia M.

Tissue Antigens. 2014 Jan;83(1):1-9. doi: 10.1111/tan.12280. Review.

PMID:
24355002
11.

Do the peptide-binding properties of diabetogenic class II molecules explain autoreactivity?

Suri A, Levisetti MG, Unanue ER.

Curr Opin Immunol. 2008 Feb;20(1):105-10. Epub 2007 Dec 21. Review.

12.

Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes.

Mannering SI, Wong FS, Durinovic-Belló I, Brooks-Worrell B, Tree TI, Cilio CM, Schloot NC, Mallone R; Immunology of Diabetes Society T-Cell Workshop Committee..

Clin Exp Immunol. 2010 Nov;162(2):197-209. doi: 10.1111/j.1365-2249.2010.04237.x. Epub 2010 Sep 15. Review.

13.

Advances in the etiology and mechanisms of type 1 diabetes.

Pugliese A.

Discov Med. 2014 Sep;18(98):141-50. Review.

14.

T cell epitopes and post-translationally modified epitopes in type 1 diabetes.

McGinty JW, Marré ML, Bajzik V, Piganelli JD, James EA.

Curr Diab Rep. 2015 Nov;15(11):90. doi: 10.1007/s11892-015-0657-7. Review.

15.

Zinc transporter 8 (ZnT8) and β cell function.

Davidson HW, Wenzlau JM, O'Brien RM.

Trends Endocrinol Metab. 2014 Aug;25(8):415-24. doi: 10.1016/j.tem.2014.03.008. Epub 2014 Apr 18. Review.

16.

Of the multiple mechanisms leading to type 1 diabetes, T cell receptor revision may play a prominent role (is type 1 diabetes more than a single disease?).

Wagner DH.

Clin Exp Immunol. 2016 Sep;185(3):271-80. doi: 10.1111/cei.12819. Epub 2016 Jul 25. Review.

PMID:
27271348
17.

Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets.

Mauvais FX, Diana J, van Endert P.

F1000Res. 2016 Apr 22;5. pii: F1000 Faculty Rev-728. doi: 10.12688/f1000research.7411.1. eCollection 2016. Review.

18.

Zinc transporters and their role in the pancreatic β-cell.

Lemaire K, Chimienti F, Schuit F.

J Diabetes Investig. 2012 Jun 6;3(3):202-11. doi: 10.1111/j.2040-1124.2012.00199.x. Review.

19.

Biomarkers in type 1 diabetes: application to the clinical trial setting.

Tooley JE, Herold KC.

Curr Opin Endocrinol Diabetes Obes. 2014 Aug;21(4):287-92. doi: 10.1097/MED.0000000000000076. Review.

20.

Where, How, and When: Positioning Posttranslational Modification Within Type 1 Diabetes Pathogenesis.

McLaughlin RJ, Spindler MP, van Lummel M, Roep BO.

Curr Diab Rep. 2016 Jul;16(7):63. doi: 10.1007/s11892-016-0752-4. Review.

Supplemental Content

Support Center